Early Alzheimer's disease (AD) detection using cerebrospinal fluid (CSF) biomarkers has been recommended as enrichment strategy for trials involving mild cognitive impairment (MCI) patients.
Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers / Marizzoni, Moira; Ferrari, Clarissa; Jovicich, Jorge; Albani, Diego; Babiloni, Claudio; Cavaliere, Libera; Didic, Mira; Forloni, Gianluigi; Galluzzi, Samantha; Hoffmann, Karl-Titus; Molinuevo, José Luis; Nobili, Flavio; Parnetti, Lucilla; Payoux, Pierre; Ribaldi, Federica; Rossini, Paolo Maria; Schönknecht, Peter; Salvatore, Marco; Soricelli, Andrea; Hensch, Tilman; Tsolaki, Magda; Visser, Pieter Jelle; Wiltfang, Jens; Richardson, Jill C; Bordet, Régis; Blin, Olivier; Frisoni, Giovanni B.; The PharmaCog, Consortium. - In: JOURNAL OF ALZHEIMER'S DISEASE. - ISSN 1387-2877. - 2018:(2018), pp. 1-12. [10.3233/JAD-180152]
Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers
Jovicich, Jorge;
2018-01-01
Abstract
Early Alzheimer's disease (AD) detection using cerebrospinal fluid (CSF) biomarkers has been recommended as enrichment strategy for trials involving mild cognitive impairment (MCI) patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
Marizzoni et al., JAD180152.pdf
accesso aperto
Tipologia:
Post-print referato (Refereed author’s manuscript)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
330.78 kB
Formato
Adobe PDF
|
330.78 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
